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Abstract: (1) Background: Dental calculus works as a niche wherein pathogenic bacteria proliferate
in the oral cavity. Previous studies revealed the anticalculus activity of pyrophosphates, however
there was no clinical study that evaluated microbiome changes associated with calculus inhibition.
Therefore, the aim of this randomized clinical trial was to evaluate the calculus inhibition of
pyrophosphate-containing toothpaste and its effect on oral microbiome changes. (2) Methods: Eighty
subjects with a calculus index ≥2 on the lingual of the mandibular anterior tooth were randomly
allocated to the test group that pyrophosphate-containing toothpaste was given to or the placebo
control group. Full mouth debridement and standardized tooth brushing instruction were given
before the allocation. Plaque index, gingival index, calculus index, probing depth, and bleeding on
probing were measured at the baseline, and at 4, 8 and 12 weeks. Genomic DNA was extracted from
the plaque samples collected at the baseline and at 12 weeks, and 16S ribosomal RNA gene amplicon
sequencing was applied for microbiome analysis. (3) Results: None of the clinical parameters showed
significant differences by visits or groups, except the plaque index of the test group, which reduced
significantly between 4 and 12 weeks. A significant difference of microbiome between the baseline and
12 weeks was observed in the test group. Between baseline and 12 weeks, the proportion of Spirochetes
decreased in the control group, and the proportions of Proteobacteria, Fusobacteria and Spirochetes
in the phylum level and the proportions of Haemophilus, Fusobacterium and Capnocytophaga in the
genus level decreased in the test group. In the test group, as plaque index decreased, Streptococcus
increased, and Fusobacterium and Haemophilus parainfluenza decreased. (4) Conclusion: The use
of pyrophosphate-containing toothpaste effectively inhibited the dysbiosis of the oral microbiome
and the proliferation of pathogenic species in periodontal disease. Clinically, plaque formation in
the pyrophosphate-containing toothpaste group was effectively decreased, however there was no
significant change in calculus deposition.
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1. Introduction
Periodontitis is the result of the host immune response against microbial challenge caused by oral
microbiome dysbiosis [1]. It is now widely accepted that periodontal inflammation is due to the collapse
of homeostasis in the healthy oral microbiome, not an infection caused by some specific pathogenic
bacteria [2]. Through previous observational studies, it was found that pathogenic anaerobic species
and the diversity of the oral microbiome are increased in periodontitis patients [3,4]. The increase in
pathogenic microbial challenge caused by dysbiosis intensifies periodontal inflammation, and vice
versa, periodontal tissue destruction caused by inflammation offers a favorable microenvironment for
dysbiosis, with abundant nutrition from the tissue breakdown products [1].
Dental calculus is a crystallized product of calcium phosphate supersaturation, thus calculus
itself has not been recognized as a pathogen of periodontal disease. However, since the surface of the
calculus is rough, a plaque layer is always formed in the oral environment, and as a result, dental
calculus acts as a niche of bacterial proliferation, providing a favorable environment for pathogenic
dysbiosis [5]. For this reason, the aim of clinical treatment procedures for periodontal disease, such as
scaling and root planning, is to remove and inhibit calculus deposition from the tooth surface [6].
Previous studies have reported that the application of pyrophosphate in self-performed plaque
control can inhibit the formation of dental calculus [7]. Pyrophosphate interrupts the conversion of
amorphous calcium phosphate to hydroxyapatite, which consists of dental calculus [8]. With the
use of the pyrophosphate-containing dentifrice, a previous study reported that the formation of
calculus was reduced by 40% after a year [9]. In addition to the reduced amount of calculus, it was
confirmed by scanning electron microscope imaging that the structure of calculus was less compact
when pyrophosphate was applied [10].
It is clear that the regular removal of dental calculus as a part of maintenance therapy
helps in maintaining periodontal health [11]. Furthermore, various studies support the inference
that periodontal inflammation interacts with systematic diseases, such as diabetes mellitus and
cardiovascular disease [12,13]. For this reason, not only the removal of calculus but also the inhibiting
of the deposition of calculus through proper supportive periodontal therapy are important factors in
maintaining periodontal health, and its related systematic health [14].
The ultimate purpose of inhibiting dental calculus formation is to prevent pathogenic changes in
the oral microbiome, which lead to periodontal disease. Thus, in addition to the evaluation of clinical
calculus formation, the evaluation of pathogenic changes in the oral microbiome is necessary. To the
best of our knowledge, there has been no clinical study that evaluates calculus inhibition and the
associated microbiome changes. Therefore, the aim of the present study was to evaluate the calculus
inhibition of pyrophosphate-containing toothpaste clinically and its effect on oral microbiome changes.
2. Materials and Methods
2.1. Study Design and Population
This study was designed as a double-blinded placebo-controlled randomized clinical trial.
The standardization of clinical measurement between investigators was ensured via calibration
meetings before the experiment. All procedures followed the Declaration of Helsinki and good clinical
practice guidelines and were approved by the Institutional Review Board of the Yonsei University Dental
Hospital (2-2017-0049). Eighty subjects were enrolled from the Department of Periodontology, Yonsei
University Dental Hospital, from April 2018 to January 2019. Before enrollment, all participants were
informed about the nature of the study, and an informed consent form was obtained. The CONSORT
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flowchart is presented in Figure 1. At the screening, clinical index measurement, plaque collection and
full mouth debridement with ultrasonic scaler were performed before allocation.
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2.3. Randomization and Blinding
The participants were randomly allocated to one of two study groups, forty patients in each group,
by a random numbering sequence generated with web-based software (www.sealedenvelope.com).
A double-blind study was performed so that the examiners were not involved in the group assignment.
Before the assignment, standardized tooth brushing instruction was given to all participants. Follow up
visits were at 4 weeks (Visit 2), 8 weeks (Visit 3) and 12 weeks (Visit 4). Up until 12 weeks, all participants
were required to use the given toothpaste according to the assignment only.
• Test group: Toothpaste containing 3.4% tetrasodium pyrophosphate was given.
• Control group: Placebo toothpaste without pyrophosphate wa given.
Except for tetrasodium pyrophosphate, the ingredients of the toothpaste in both groups
were identical.
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2.4. Inclusion and Exclusion Criteria
This study was performed on patients with visually confirmed dental calculus and who were
diagnosed as having gingivitis or incipient periodontitis. The further inclusion criteria were as follows:
(1) being >18 and <65 years of age and in good general health, (2) having a minimum of 18 teeth,
(3) having calculus index ≥2 on the lingual surface of mandibular anterior teeth, and (4) being able to
perform adequate tooth brushing. The exclusion criteria were as follows: (1) not providing written
informed consent, (2) being pregnant or lactating, (3) having an oral mucosal disease such as lichen
planus, (4) being diagnosed as chronic, moderate or advanced periodontitis, (5) smoking, (6) being
allergic to the chemical ingredient of conventional toothpaste and (7) being judged as being unsuitable
for study inclusion by the clinician for some other reasons.
2.5. Baseline Measurement and Follow up Measurements
Plaque collection was performed according to the previous study [17]. One hour before collection,
oral hygienic control, such as mouth rinses or brushing and eating, was prevented. Before swabbing,
participants rinsed their mouths with pure water. Dental plaque samples were collected by swabbing
along the lingual side of the lower anterior teeth surfaces. The acquired swabs were immediately
stored at −80 ◦C until being analyzed.
After plaque collection, a representative six Ramfjord teeth (#16, 21, 24, 36, 41, and 44) were
examined for clinical index measurement. Plaque index (PI, Loe, 1967), gingival index (GI, Loe. 1967),
calculus index (CI, Greene and Vermillion, 1964), probing depth (PD) and bleeding on probing (BOP)
were scored for each Ramfjord tooth [18,19]. Since lingual side of tooth #41 clinically shows pronounced
deposition of dental calculus due to inaccessibility of tooth brushing and proximity to sublingual
saliva gland, CI of #41 lingual was analyzed separately in addition to total CI. After clinical index
measurement, full mouth debridement and standardized tooth brushing instruction were performed,
and patients were randomly allocated to the test or the control group.
At the 4-weeks and 8-weeks follow up visits, only clinical index measurement was performed.
At 12 weeks, plaque collection and clinical index measurement were performed (Figure 2).
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Figure 2. Clinical photo of #41 lingual at baseline (A), 4 weeks (B) and 12 weeks (C) of control group.
Since full mouth debridement was done at baseline, calculus observed at 4 weeks and 12 weeks are
newly deposited calculus after debridement. Deposited calculus are pointed out with yellow arrows
in (A).
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proteinase inactivation. Afterward, 4 5 µL of 100% ethanol was dde per tube, and the samples were
vigorously mixed by vortexing. The subsequent steps followed the purification of total DNA from
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animal tissues (Spin-Column Protocol) of the kit. Finally, the extracted gDNA was eluted with 30 µL of
AE buffer per tube and stored at −20 ◦C until use.
2.7. Sample Preparation and Sequencing
PCR with primers 518F and 927R was used to amplify the V4–V5 region of the bacterial 16S
rRNA gene. The primer sequences for 518F and 927R are (5′-CCAGCAGCYGCGGTAAN-3′) and
(5′-CCGTCAATTCNTTTRAGT-3′), respectively. The thermal cycling conditions were as follows: initial
denaturation (95 ◦C for 3 min), 33 cycles (95 ◦C for 30 s, 55 ◦C for 30 s, and 72 ◦C for 5 min), and final
extension (72 ◦C for 5 min). Using AMPure XP beads (Beckman Coulter Ltd., High Wycombe, UK),
the PCR products were purified. To barcode each sample, using the i7 and i5 index adapters of the
Illumina Nextera XT Index Kit v2, indexing PCR was performed. Amplification cycles were performed
only 8 times and the other thermal cycling conditions were the same as described above. Purifying the
products was performed under the same conditions. Using the Illumina MiSeq platform, paired-end
sequencing (2 × 300 bp) was performed by Macrogen Inc. (Seoul, Korea).
2.8. Microbiome Analysis and Statistical Anaylsis
Microbiome sequences were processed using the plugins in the QIIMETM 2 (Quantitative Insights
Into Microbial Ecology) pipeline 2019.7 [20]. Primer sequences were removed from the bacterial
sequences with cutadapt 2.3 (Martin 2011 [21]) by using the default values. Reads that contained no
bacterial primer sequence or a poor-quality primer sequence (i.e., error rate >10%) were eliminated at
this step [21]. Paired-end sequence reads were denoised and merged at the truncated position of 222bp
and 171bp for forward and reverse read sequences, respectively, via the dada2 denoise-paired process,
whereby bacterial amplicon sequence variants (ASVs) were identified [22]. The feature-classifier
classify-sklearn (4) was used to assign bacterial taxonomy via the Greengenes database at 99% sequence
similarity (mitochondrial or chloroplastic ASVs were eliminated). Aligning of the ASVs was performed
by using the phylogeny align-to-tree-mafft-fasttree. With a rarefied depth of 2164 reads per sample,
α-diversity (Chao1; observed ASVs) and β-diversity were determined.
2.9. Statistical Anaylsis
For clinical parameters, statistical analysis was performed with commercially available software
(IBM SPSS Statistics 23, SPSS, Chicago, IL, USA). The Mann–Whitney U test and chi-square test
were applied to compare demographic characteristic and clinical index between the control and test
groups. To assess the significant difference in the bacterial community (β-diversity) between the groups,
analysis of similarity (ANOSIM) was used. To determine the significantly different alpha diversities and
taxonomies between the groups, the Wilcoxon’s rank-sum test or the t-test was performed. To identify
the significant ASVs in each group, linear discriminant analysis (LDA) and effect size (LEfSe) analysis
was carried out with an LDA score ≥2.5. Linear regression analysis of specific strains and PI was
performed. Since buccal side of teeth clinically show lessened deposition of dental plaque due to
easiness of oral hygiene control, the regression analysis was done separately for buccal and lingual PI.
3. Results
A total of 80 participants were enrolled in the study. Five participants in the control group and
one in the test group were excluded from the analysis due to missing follow-up visits. In consequence,
the study was completed with 74 participants (n = 39 and 35 in the test and control groups, respectively).
The demographic characteristics of the participants are presented in Table 1. There was no significant
difference in age and distribution of gender.
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Table 1. Demographic character of participants.
Control (n = 35) Test (n = 39) p Value(Control vs. Test)
Male/Female 14/21 19/20 0.14
Age 37.08 ± 11.08 33.72 ± 11.74 0.49
Ages of participants are presented as mean ± standard deviation. (p value = 0.14 > 0.05 and 0.49 > 0.05 in age and
distribution of gender, respectively)
The clinical parameters are presented in Table 2. None of the clinical parameters differed
significantly between the test and control groups at the baseline and each follow-up visit. Changes in
the clinical parameters are depicted in Figure 3. Since full mouth debridement was done at the baseline,
all clinical parameters were reduced between the baseline and 4 weeks. Reduced clinical parameters
were maintained until 12 weeks in both the test and control groups. The PI of the test group was
reduced significantly between 4 weeks (2.77) and 12 weeks (1.86), while there was no statistically
significant change in the PI of the control group. Except for PI, there were no significant changes in
clinical parameters between 4 weeks and 12 weeks in either the test or the control group. Also, there
was no significant difference between clinical parameters of the test and the control group in all visits.









Control 3.84 ± 1.90 2.50 ± 1.68 2.26 ± 1.61 2.09 ± 1.52 0.33
Test 3.56 ± 1.82 2.77 ± 2.07 2.32 ± 1.97 1.86 ± 1.46 * 0.037
p value
(Test vs. Control) 0.35 0.74 0.87 0.52
CI
Control 1.66 ± 1.29 0.50 ± 0.54 0.61 ± 0.84 0.48 ± 0.38 0.58
Test 1.43 ± 1.25 0.47 ± 0.50 0.53 ± 0.60 0.47 ± 0.42 0.73
p value
(Test vs. Control) 0.26 0.90 0.78 0.70
CI 41
Control 4.26 ± 1.56 2.40 ± 2.44 1.83 ± 1.92 2.14 ± 1.65 0.92
Test 4.18 ± 2.15 2.15 ± 2.29 2.10 ±2.26 2.33 ± 2.20 0.63
p value
(Test vs. Control) 0.66 0.75 0.84 0.98
GI
Control 5.43 ± 2.54 4.19 ± 2.34 4.32 ± 2.42 4.03 ± 2.73 0.92
Test 5.51 ± 2.98 4.30 ± 2.73 3.73 ± 2.64 3.42 ± 2.45 0.14
p value
(Test vs. Control) 0.83 0.78 0.42 0.28
PD
Control 2.68 ± 0.30 2.48 ± 0.29 2.53 ± 0.25 2.48 ± 0.27 0.93
Test 2.61 ± 0.32 2.55 ±0.29 2.55 ± 0.27 2.56 ± 0.21 0.67
p value
(Test vs. Control) 0.37 0.47 1.00 0.27
BOP
Control 1.77 ± 1.16 1.07 ± 0.83 1.11 ± 0.89 0.93 ± 0.88 0.40
Test 1.79 ± 1.40 1.23 ± 0.98 1.06 ± 0.98 0.84 ± 0.81 0.08
p value
(Test vs. Control) 0.93 0.53 0.51 0.56
Clinical parameters are presented as mean ± SD. * Significant difference from 4 weeks. PI, average of plaque index
per tooth; CI, average of calculus index per tooth; CI 41, average of calculus index of #41 tooth lingual; GI, average
of gingival index per tooth; PD, average of probing depth per site; BOP, average of bleeding on probing per tooth.
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Figure 3. Changes of clinical parameters. Since full mouth debridement was given at a baseline visit,
all clinical parameters were reduced significantly between baseline and 4 weeks. At the follow-up visits,
all parameters showed no difference between test and control group. Only the plaque index of the test
group between 4 weeks and 12 weeks showed a significant difference (* p < 0.05), while the other clinical
parameters in each group did not show a significant difference among 4, 8 and 12 weeks of follow-up.
The data presented in the graph for plaque index, gingival index, calculus index, and bleeding on
probing are average per tooth, while those of probing depth are average per site.
At baseline, the microbiome of the test and control groups were similar (Figure 4A). In the control
group, there was no significant difference in microbiome between baseline and 12 weeks (ANOSIM,
p = 0.689; Figure 4B Left). In contrast, a significant difference in microbiome between the baseline and
12 weeks was observed in the test group (ANOSIM, p = 0.001; Figure 4B, Right). The alpha diversity of
the control and the test group was reduced between baseline and 12 weeks, but there was no statistical
significance (Figure 4C).
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Figure 4. Evolution and richness of dental plaque microbiome. Principal coordinate analysis of
microbiomes according to sampling time (A) and groups (B). (A) At baseline and 12 weeks, there
was no significant difference between the control and test group. (B) In the test group, there was a
significant difference between baseline and 12 weeks (ANOSIM, p = 0.001 < 0.05). (C) α-diversity of the
control and test group at baseline and 12 weeks.
In detail, a total of 21 phyla and 205 genera was identified in the total plaque samples.
The phylum-level taxonomic analysis of the test group and the control group is sum arized in
Table 3. At the phylum level, Firmicutes and Proteobacteria were dominant in both the test and the
control group. In the control group, the proportion of Spirochaetes decreased significantly between the
baseline and 12 weeks. In the test group, the proportions of Proteobacteria, Fusobacteria and Spirochetes
decreased significantly between the baseline and 12 weeks. In contrast, the proportion of Firmicutes in
the test group increased significantly between the baseline and 12 weeks.
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Table 3. Phylum-level taxonomic analysis.
Baseline 12 Weeks
Control (%) Test (%) Total (%) Control (%) Test (%) Total (%)
Firmicutes 33.43 29.03 31.14 37.00 41.23 *** 39.17
Proteobacteria 37.8 40.04 38.97 33.63 28.45 *** 30.97
Actinobacteria 18.17 18.57 18.38 20.70 22.96 21.86
Bacteroidetes 7.94 8.67 8.32 6.71 5.81 6.25
Fusobacteria 2.48 2.93 2.71 1.84 1.41 ** 1.62
Spirochaetes 0.11 0.55 0.34 0.01 ** 0.03 * 0.02
TM7 0.02 0.03 0.03 0.07 *** 0.07 0.07
Others 0.05 0.17 0.11 0.04 0.04 0.04
Average proportions (%) of each phyla in total microbiome are presented. * Statistically significant difference
between baseline and 12 weeks (p < 0.05); ** Statistically significant difference between baseline and 12 weeks
(p < 0.01); *** Statistically significant difference between baseline and 12 weeks (p < 0.001).
The genus-level taxonomic analysis of the test group and the control group is summarized in
Table 4. At the genus level, Streptococcus was dominant in both the test and the control group. In the
control group, there was no significant change in genus distribution. In the test group, the proportion
of Streptococcus was significantly increased between baseline and 12 weeks. The proportions of
Haemophilus, Fusobacterium and Capnocytophaga were significantly decreased between baseline and
12 weeks.
Table 4. Genus-level taxonomic analysis.
Baseline 12 Weeks
Control (%) Test (%) Total (%) Control (%) Test (%) Total (%)
Streptococcus 30.00 25.65 27.73 33.15 31.69 ** 35.48
Lautropia 12.37 12.63 12.51 8.18 10.62 8.81
Actinomyces 7.61 7.59 7.60 8.99 8.69 9.74
Haemophilus 7.37 9.42 8.44 6.08 6.44 ** 4.53
f_Neisseriaceae 6.92 6.77 6.84 6.70 6.38 5.94
Neisseria 5.41 5.67 5.54 7.25 5.98 6.41
Rothia 4.8 4.93 4.87 4.84 5.23 5.57
Corynebacterium 4.55 4.98 4.77 4.46 4.65 4.53
Capnocytophaga 3.97 3.73 3.85 3.38 3.37 * 2.91
f_Propionibacteriaceae 1.08 0.95 1.01 2.20 1.42 1.82
Kingella 1.35 1.45 1.40 1.27 1.37 1.33
f_Weeksellaceae 1.38 1.09 1.23 1.45 1.26 1.28
Fusobacterium 1.22 2.21 1.73 0.77 1.25 ** 0.79
Others 11.98 12.93 12.48 11.28 11.65 10.87
Average proportions (%) of each genus in total microbiome are presented. * Statistically significant difference
between baseline and 12 weeks (p < 0.05); ** Statistically significant difference between baseline and 12 weeks
(p < 0.001).
Linear discriminant analysis effect sized (LEfSe) was applied for amplicon sequence variants
(ASVs) level analysis. In total, 29 ASVs were more abundant at the baseline, and 20 ASVs were
more abundant at 12 weeks. The LEfSe results are summarized in Figure S1. The species that show
significant changes in LEfSe between baseline and 12 weeks are summarized in Table S1. In the control
group, a small number of species showed significant change between baseline and 12 weeks. In the test
group, in contrast to the control group, a large number of species showed significant change between
baseline and 12 weeks. Considering the result of the taxonomic analysis, Haemophilus parainfluenzae
and Fusobacterium were significantly decreased between baseline and 12 weeks, while Streptococcus
was significantly increased in the test group.
Linear regression analysis of specific strains and PI values was performed and is presented in
Figure 5. PI values that showed a significant change were selected as a clinical indicator, and the
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taxa that showed a significant change in LEfSe between baseline and 12 weeks were selected. In the
control group, only in buccal, it was confirmed that the PI value decreased as Fusobacterium decreased
at 12 weeks as compared to baseline, and decreased as the Streptococcus increased. In the buccal of the
test group, the PI value decreased as Haemophilus parainfluenzae decreased at 12 weeks compared to
baseline. On the contrary, it was confirmed that the PI value decreased as Streptococcus increased. In the
case of lingual, it was confirmed that the PI value decreased as Fusobacterium decreased at 12 weeks
compared to the baseline. On the contrary, the PI value decreased as Streptococcus increased.
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4. Discussion
Through this study, it was confirmed that the use of pyrophosphate-containing toothpaste
effectively inhibited the dysbiosis of the oral microbiome and the proliferation of pathogenic species
such as fusobacterium and capnocytophaga. Clinically, the plaque formation of pyrophosphate-containing
toothpaste group was effectively decreased, however there was no significant change in calculus
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deposition. The use of pyrophosphate-containing toothpaste demonstrated its efficacy in maintaining
a healthy oral microbiome, which is related to the prevention of periodontal disease.
Pyrophosphate inhibits dental calculus formation by interrupting the conversion of amorphous
calcium phosphate to hydroxyapatite crystal [8]. Since calculus has a rough surface, a new bacterial
plaque attaches to the generated calculus [5]. Plaques absorb calcium ions and phosphates in oral
fluid to be calcified and changed to hard calculus. Calculus offers a favorable microenvironment for
the proliferation of pathogenic species, which are mostly anaerobic, so they cannot survive without
polymicrobial synergy and dysbiosis [2].
In the present study, the use of pyrophosphate-containing toothpaste did not result in a significant
difference in CI. Since CI is non-continuous and has ordinal values of integers from 0 to 3, it is difficult
to express an intermediate state between the criteria of the scores and the quality of calculus. Thus, only
a dramatic change in calculus deposition can be reflected in the change of CI. Since various factors, such
as the composition and secretion rate of saliva, and diets, effect dental calculus formation, there was
a limitation in showing significant changes in calculus formation with pyrophosphate-containing
toothpaste [5].
Unlike CI, a significant difference in PI was observed. When calculus is produced in the oral cavity,
the surface always remains covered by non-calcified dental plaque [6]. The inhibition of crystallization
by pyrophosphate results in a less compact surface of the deposited calculus [10]. This phenomenon
makes it difficult for plaque to accumulate on the surface of calculus, and the attachment between
plaque and calculus is weakened. Weak plaque–calculus attachment allows easy plaque removal
with the same tooth brushing method. With this mechanism, the use of pyrophosphate-containing
toothpaste not only inhibits plaque deposition, but also facilitates the removal of plaque.
In the analysis of phylum level, the use of pyrophosphate-containing toothpaste decreased
the portion of Spirochaetes in the oral microbiome, while the control group showed an increase of
Spirochaetes. According to previous studies comparing the bacterial profiles of periodontitis and healthy
patients, Spirochaetes were highly associated with the diseased state [4]. Spirochaetes are small, have
motility, and inhibit the polymorphonuclear leukocyte (PMNL) invasion of the host, so they can
easily invade the periodontal tissue and avoid host immune surveillance [23]. Among the Spirochaetes,
the Treponema genera, such as Treponema denticola and Treponema vincentti, are among the more highly
documented periodontal pathogenic species [24]. In particular, Treponema denticola is a representative
periodontal pathogenic species that is classified as ‘red complex’ with Porphyromonas gingivalis and
Tannerella forsythia [25]. Red complex species induce tissue destructive enzymes and immune responses,
and products from tissue destruction create acidic and anaerobic conditions. Since most pathogenic
species are anaerobic, the anaerobic condition induced by tissue destruction is hospitable for the
dysbiotic and virulent change of the microbiome [1].
In the analysis of the genus level, the proportion of Streptococcus was significantly increased with
the use of pyrophosphate-containing toothpaste. Streptococcus is highly associated with a healthy state,
and suppresses the increase in ‘red complex’ through antagonistic action [4]. Since Porphyromonas
gingivalis cannot maintain its growth below pH 6.5, the acidic environment in which Streptococcus
mutans forms in its metabolism inhibits the pathogenic change related to Porphyromonas gingivalis [26].
Furthermore, a previous in vitro study showed that the presence of Streptococcus inhibits the growth of
Tannerella forsythia and Prevotella intermedia [27]. With these mechanisms, Streptococcus protects the
homeostasis of the microbiome from dysbiosis in the direction of increasing pathogenic species [28].
In the aspect of dental caries, Streptococcus mutans is well-known as a key cariogenic species, so that
there could be a limitation to simply regarding Streptococcus mutans as a protector of a healthy
microbiome [29]. However, a recent study based on DNA sequencing failed to find a difference in
Streptococcus mutans proportion between caries-active and caries-free subjects [30].
Pyrophosphate-containing toothpaste reduced Fusobacterium and Capnocytophaga. Fusobacterium
can co-adhere with most of the species, and is an intermediate between the early colonizer and late
colonizer [31]. Once the pellicles are formed, the early colonizer, mostly Streptococcus, is the first to
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attach. Streptococcus is antagonistic to ‘red complex’, but Fusobacterium acts as an intermediary, allowing
the attachment of ‘red complex’. In addition to assisting pathogenic bacteria in attaching, Fusobacterium
itself upregulates the expression of tissue destructive enzymes, such as matrix metalloproteinase,
and secretes serine protease, causing tissue destruction [32]. Capnocytophaga degrades IgA and IgG,
and induces the alteration of PMNL function [33]. Previous studies found a significant increase in
Capnocytophaga in various forms of periodontitis, compared to the healthy state [34,35].
Linear regression analysis confirmed that the PI value and the specific bacteria were closely related.
Haemophilus parainfluenzae and Fusobacterium were negatively related to PI, while streptococcus was
positively related to PI. Haemophilus parainfluenzae is known as an opportunistic pathogen and is related
to the progression of the periodontitis [36] Furthermore, as previously discussed, Streptococcus and
Fusobacterium are in an antagonistic relation. However, there is a limitation to interpretation, as plaque
accumulation and changes of such species are in a causal relationship. From our study, we could
regard Streptococcus mutans as a beneficial indicator, and Haemophilus parainfluenzae and Fusobacterium
as harmful indicators. However, further pathological investigation is needed to prove the causal
relationship between such species and plaque-induced gingivitis.
Besides the observational study of bacteria, Hsu et al. reported that pyrophosphate suppresses
bacterial growth by the inhibition of F-ATPase and chelation of Mg2+ [37]. F-ATPase transports protons
out of cells, so it is related to the acid tolerance of bacteria [38]. The homeostasis of Mg2+ stabilizes
membrane and macromolecular complexes. Since Gram-negative and Gram-positive have different
regulators for low extracytoplasmic Mg2+, the chelation of Mg2+ has different effects. In Gram-negative
species, low Mg2+ promotes the transcription of several genes involved in virulence and adaptation.
In Gram-positive species, sensor kinase is inactivated by low Mg2+, leading to the inactivation of
virulence-associated genes [39]. Therefore, the inhibition of F-ATPase and low concentrations of Mg2+
due to chelation are deemed to induce the alteration of the composition of the microbiome, rather than
just their bactericidal effect.
To the best of our knowledge, this study is the first randomized clinical trial to analyze the effect
of pyrophosphate on the oral microbiome through 16S ribosomal RNA gene amplicon sequencing.
The culturing method, which most of the previous studies used, has the limitation that it cannot replicate
the complex oral microbiome because only one species can be cultured in the plate. Furthermore,
there is the limitation that most of the pathogenic species are uncultivable. Using 16S ribosomal RNA
gene amplicon sequencing offers comprehensive and accurate information about the oral microbiome,
which interacts actively between species and the surrounding conditions in the oral environment.
5. Conclusions
In conclusion, the use of pyrophosphate-containing toothpaste effectively inhibited plaque
accumulation, however, there was no significant inhibition in calculus deposition. Microbiologically
pyrophosphate-containing toothpaste decreased pathogenic species in the oral microbiome.
Anti-mineralization effect of pyrophosphate may count for plaque inhibition and preventing pathogenic
dysbiosis. The use of pyrophosphate-containing toothpaste can be adequate for maintaining a
periodontally healthy state.
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